Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 120

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 120
---
 applicable to any industry in which Aadi Sub conducts business, or any action taken for the purpose of complying with GAAP or any law; |

| • |     | any failure, in and of itself, by Aadi Sub or Aadi to meet (1) any public estimates or expectations of                                                                                                                                                 
 Aadi’s or Aadi Sub’s revenue, earnings or other financial performance or results of operations for any period; or (2) any internal budgets, plans, projections or forecasts of its revenues, earnings or other financial performance or                
 results of operations (it being understood that the cause of any such failure may be deemed to constitute, in and of itself, a Company Material Adverse Effect and may be taken into consideration when determining whether a Company Material Adverse 
 Effect has occurred unless otherwise excluded pursuant hereto);                                                                                                                                                                                        |

| • |     | (1) regulatory, manufacturing or clinical changes, events or developments or other actions resulting from any                                                                                                                                                                                                                                      
 nonclinical or clinical studies sponsored by Aadi Sub or any competitor of Aadi Sub, results of meetings with the FDA or other governmental authority (including any communications from any governmental authority in connection with such meetings), or                                                                                          
 any increased incidence or severity of any previously identified side effects, adverse effects, adverse events or safety observations or reports of new side effects, adverse events or safety observations with respect to Aadi Sub’s or any                                                                                                      
 competitor’s product candidates, (2) the determination by, or the delay of a determination by, the FDA or any other governmental authority, or any panel or advisory body empowered or appointed thereby, with respect to the clinical hold,                                                                                                       
 acceptance, filing, designation, approval, clearance, non-acceptance, hold, refusal to file, refusal to designate, non-approval, disapproval or non-clearance of any of Aadi Sub’s or any competitor’s product candidates, (3) FDA approval (or other clinical or regulatory developments), market entry or threatened market entry of any product 
 competitive with or related to any of Aadi Sub’s products or product candidates, or any guidance, announcement or publication by the FDA or other governmental authority relating to any product candidates of Aadi Sub or any competitor, or                                                                                                      
 (4) any manufacturing or supply chain disruptions or delays in manufacturing validation affecting products or product candidates of Aadi Sub or developments relating to reimbursement, coverage or payor rules with respect to any product or                                                                                                     
 product candidates of Aadi Sub or the pricing of products, in each case other